CR20210032A - Compuestos - Google Patents

Compuestos

Info

Publication number
CR20210032A
CR20210032A CR20210032A CR20210032A CR20210032A CR 20210032 A CR20210032 A CR 20210032A CR 20210032 A CR20210032 A CR 20210032A CR 20210032 A CR20210032 A CR 20210032A CR 20210032 A CR20210032 A CR 20210032A
Authority
CR
Costa Rica
Prior art keywords
compounds
compound
formula
pharmaceutical salt
pharmaceutical
Prior art date
Application number
CR20210032A
Other languages
English (en)
Inventor
Helen Rachel Lagiakos
Benjamin Joseph Morrow
Michelle Ang Camerino
Scott Raymond Walker
Ylva Elisabet Bergman Bozikis
Catherine Fae Hemley
Paul Anthony Stupple
Richard Charles Foitzik
Original Assignee
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctxt Pty Ltd filed Critical Ctxt Pty Ltd
Publication of CR20210032A publication Critical patent/CR20210032A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

<p><strong>COMPUESTOS</strong></p> <p>Un compuesto de formula (I),</p> <p><img src="https://patentscope.wipo.int/search/docs2/pct/WO2019243491/pic/lg5mRajToAcysri0KI_hsYAyaa6xOVjVomEnLWMaS_J6ESs_0PRVB7F_a6_PCGo4N_VZxE5dPiA02F7sf72XtDnX2DJu9HIGBV5M6TjF2Bhbj5xXqZok9yXXkwHRZkwvaRx-Q0niUS4AWe81K-CI5ggvTeeV3kcQiz8XUYj7MiU?docId=id00000051793240" /></p> <p> </p> <p>o una sal farmaceutica del mismo:</p>
CR20210032A 2018-06-20 2019-06-20 Compuestos CR20210032A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1810092.5A GB201810092D0 (en) 2018-06-20 2018-06-20 Compounds
PCT/EP2019/066337 WO2019243491A1 (en) 2018-06-20 2019-06-20 Compounds

Publications (1)

Publication Number Publication Date
CR20210032A true CR20210032A (es) 2021-02-11

Family

ID=63042663

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210032A CR20210032A (es) 2018-06-20 2019-06-20 Compuestos

Country Status (37)

Country Link
US (2) US20200039945A1 (es)
EP (2) EP3810602B1 (es)
JP (1) JP2021529738A (es)
KR (1) KR20210022655A (es)
CN (1) CN112334466A (es)
AR (1) AR114972A1 (es)
AU (1) AU2019289888A1 (es)
BR (1) BR112020025869A2 (es)
CA (1) CA3101238A1 (es)
CL (1) CL2020003219A1 (es)
CO (1) CO2020014586A2 (es)
CR (1) CR20210032A (es)
CU (1) CU20200096A7 (es)
DK (1) DK3810602T3 (es)
DO (1) DOP2020000249A (es)
EA (1) EA202092451A1 (es)
EC (1) ECSP20075270A (es)
FI (1) FI3810602T3 (es)
GB (1) GB201810092D0 (es)
GE (1) GEP20227403B (es)
HR (1) HRP20231467T1 (es)
IL (1) IL279554A (es)
LT (1) LT3810602T (es)
MA (1) MA52948B1 (es)
MD (1) MD3810602T2 (es)
MX (1) MX2020012723A (es)
NI (1) NI202000092A (es)
PE (1) PE20210181A1 (es)
PH (1) PH12020500673A1 (es)
PL (1) PL3810602T3 (es)
PT (1) PT3810602T (es)
RS (1) RS64932B1 (es)
SG (1) SG11202010450VA (es)
SI (1) SI3810602T1 (es)
TW (1) TWI826471B (es)
UY (1) UY38270A (es)
WO (1) WO2019243491A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471271A1 (en) 2017-10-16 2019-04-17 Acoustical Beauty Improved convolutions of digital signals using a bit requirement optimization of a target digital signal
CR20210627A (es) * 2019-06-18 2022-02-08 Pfizer Derivados de benzisoxazol sulfonimada
AU2020295006B2 (en) * 2019-06-19 2023-11-09 Ctxt Pty Ltd Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
JP2022540434A (ja) * 2019-07-12 2022-09-15 キャノピー グロウス コーポレイション カンナビノイド誘導体
BR112023000687A2 (pt) 2020-07-15 2023-02-07 Pfizer Métodos e combinações de inibidores de kat6 para o tratamento de câncer
AU2022278733A1 (en) * 2021-05-21 2023-11-30 Aurigene Oncology Limited Fused isoxazolyl compounds as kat6a inhibitors
WO2023280182A1 (zh) * 2021-07-05 2023-01-12 杭州英创医药科技有限公司 作为kat6抑制剂的化合物
KR20240046530A (ko) 2021-08-10 2024-04-09 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 설폰아미드 유도체, 이의 제조 방법 및 이의 의학적 용도
TW202334163A (zh) * 2021-11-16 2023-09-01 香港商英矽智能科技知識產權有限公司 離胺酸乙醯基轉移酶6a (kat6a)抑制劑及其用途
WO2023114710A1 (en) * 2021-12-13 2023-06-22 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
US20230303580A1 (en) * 2022-03-28 2023-09-28 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
US20230416240A1 (en) * 2022-06-16 2023-12-28 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
TR199801530T2 (xx) 1996-02-13 1998-11-23 Zeneca Limited VEGF �nhibit�rleri olarak kinazolin t�revleri.
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ATE359515T1 (de) 1997-02-12 2007-05-15 Electrophoretics Ltd Proteinmarker für lungenkrebs und deren verwendung
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CZ306810B6 (cs) 1999-02-10 2017-07-19 Astrazeneca Ab Použití chinazolinového derivátu jako inhibitoru angiogeneze
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
CA2399358C (en) 2000-02-15 2006-03-21 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
DK2385938T3 (en) * 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
RU2015143834A (ru) * 2013-03-15 2017-04-24 Дженентек, Инк. Замещенные бензоксазолы и способы их применения
RU2702113C2 (ru) * 2014-04-23 2019-10-04 Мицубиси Танабе Фарма Корпорейшн Новое бициклическое или трициклическое гетероциклическое соединение
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
US20220267260A1 (en) * 2016-11-29 2022-08-25 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
CR20210627A (es) * 2019-06-18 2022-02-08 Pfizer Derivados de benzisoxazol sulfonimada

Also Published As

Publication number Publication date
PL3810602T3 (pl) 2024-03-04
PT3810602T (pt) 2024-01-03
EP3810602A1 (en) 2021-04-28
MD3810602T2 (ro) 2024-03-31
PE20210181A1 (es) 2021-01-29
US20200039945A1 (en) 2020-02-06
GEP20227403B (en) 2022-08-10
MX2020012723A (es) 2021-05-14
KR20210022655A (ko) 2021-03-03
SI3810602T1 (sl) 2024-02-29
SG11202010450VA (en) 2021-01-28
FI3810602T3 (fi) 2023-12-21
IL279554A (en) 2021-01-31
PH12020500673A1 (en) 2021-05-31
AR114972A1 (es) 2020-11-11
MA52948B1 (fr) 2024-02-29
NI202000092A (es) 2021-03-23
EP3810602B1 (en) 2023-11-01
TW202016103A (zh) 2020-05-01
LT3810602T (lt) 2024-01-25
GB201810092D0 (en) 2018-08-08
BR112020025869A2 (pt) 2021-03-23
CL2020003219A1 (es) 2021-06-11
HRP20231467T1 (hr) 2024-03-01
DK3810602T3 (da) 2023-12-11
EA202092451A1 (ru) 2021-03-16
DOP2020000249A (es) 2021-02-28
TWI826471B (zh) 2023-12-21
CA3101238A1 (en) 2019-12-26
US20220153710A1 (en) 2022-05-19
CU20200096A7 (es) 2021-08-06
MA52948A (fr) 2021-04-28
UY38270A (es) 2020-01-31
ECSP20075270A (es) 2021-02-26
EP4335439A2 (en) 2024-03-13
CN112334466A (zh) 2021-02-05
CO2020014586A2 (es) 2021-03-08
RS64932B1 (sr) 2023-12-29
WO2019243491A1 (en) 2019-12-26
AU2019289888A1 (en) 2020-11-12
JP2021529738A (ja) 2021-11-04

Similar Documents

Publication Publication Date Title
CR20210032A (es) Compuestos
PH12018501099A1 (en) Novel biphenyl compound or salt thereof
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
PH12019502252A1 (en) Gip receptor activating peptide
BR112017006253A2 (pt) novos compostos
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
MX2020002430A (es) Compuestos inhibidores del receptor 1 del acido lisofosfatidico (lpar1).
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
EA202193015A1 (ru) Ингибиторы cdk
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
MY193239A (en) Novel b-lactamase inhibitors
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
MX2021004386A (es) Compuestos novedosos.
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2022008665A (es) Nuevo derivado de pirazol.
AU2019408336A8 (en) Phenylpyrrolidine compound and use thereof
MY194015A (en) Sodium channel blocker
EA201690908A1 (ru) Пиразолопиримидиновые соединения
MX2019007786A (es) Compuestos sustituidos de guanidina.
MX2022006984A (es) Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina.
AR125853A2 (es) Composición farmacéutica de una sal hemisulfato de un compuesto nucleotídico
SA119400353B1 (ar) مشتق بيرازول مستبدل
MY189798A (en) Novel biphenyl compound or salt thereof